Literature DB >> 9816469

Fas and Fas ligand-mediated apoptosis and its role in autoimmune diabetes.

A Signore1, A Annovazzi, R Gradini, R Liddi, G Ruberti.   

Abstract

The relationship between Fas-mediated apoptosis and Type 1 diabetes is currently under investigation. Fas/Fas ligand interaction could be involved both in the insulitis process and in beta-cell death. Nevertheless, different mechanisms appear to be involved in human Type 1 diabetes and in NOD mice. In the present work, we review recent evidence of the role of the Fas/Fas ligand system in human and NOD mouse diabetes, describing possible hypotheses for its involvement in the pathogenesis of the disease, with possible implications for therapy and islet transplantation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9816469     DOI: 10.1002/(sici)1099-0895(1998090)14:3<197::aid-dmr213>3.0.co;2-g

Source DB:  PubMed          Journal:  Diabetes Metab Rev        ISSN: 0742-4221


  4 in total

1.  Fas/FasL gene polymorphism in patients with Hashimoto's thyroiditis in Turkish population.

Authors:  M Erdogan; M Kulaksizoglu; S Ganidagli; A Berdeli
Journal:  J Endocrinol Invest       Date:  2016-08-30       Impact factor: 4.256

Review 2.  Many checkpoints on the road to cell death: regulation of Fas-FasL interactions and Fas signaling in peripheral immune responses.

Authors:  Madhu Ramaswamy; Sophia Y Cleland; Anthony C Cruz; Richard M Siegel
Journal:  Results Probl Cell Differ       Date:  2009

3.  Fas-Related Apoptosis of Peritoneal Fluid Macrophages in Endometriosis Patients: Understanding the Disease.

Authors:  Marek Gogacz; Krzysztof Gałczyński; Małgorzata Wojtaś; Izabela Winkler; Aneta Adamiak; Katarzyna Romanek-Piva; Tomasz Rechberger; Jan Kotarski
Journal:  J Immunol Res       Date:  2017-11-01       Impact factor: 4.818

4.  Fas/Fas-Ligand Interaction As a Mechanism of Immune Homeostasis and β-Cell Cytotoxicity: Enforcement Rather Than Neutralization for Treatment of Type 1 Diabetes.

Authors:  Esma S Yolcu; Haval Shirwan; Nadir Askenasy
Journal:  Front Immunol       Date:  2017-03-27       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.